WDAY — Consulting Agreement Ends for Sayan Chakraborty
Dec 2, 2025, 8:00:00 AM UTC
Summary
Sayan Chakraborty's consulting agreement with Workday, Inc. concludes on December 2, 2025, marking the end of his advisory services following his transition from the role of President, Product and Technology. His departure coincides with Gerrit Kazmaier’s appointment to the role, effective March 10, 2025. Chakraborty is expected to continue receiving his cash compensation and vesting equity awards through the end of his agreement, which reflects his significant contributions to the company during his tenure. The end of this transition period and consulting role signals a strategic leadership shift for Workday as it enhances its product and innovation strategy under Kazmaier's leadership.
Company
WORKDAY INC (WDAY)NASDAQ — Technology: Services, Software - Application: Services-Computer Processing & Data Preparation
www.workday.comSimilar Events
Transition Period Ends for Sayan Chakraborty
Sayan Chakraborty will conclude his advisory role with Workday, Inc. on June 2, 2025, assisting in the transition of duties after serving as President, Product and Technology. His retirement from this executive position was reported along with the appointment of Gerrit Kazmaier to succeed him, effective March 10, 2025. During the transition period, Chakraborty will maintain his current compensation and continue to facilitate the handover. Following the transition, he is expected to enter into a consulting agreement with Workday to provide advisory services until December 2, 2025, where he will continue to vest his prior equity awards.
Advisor TransitionEnd of Consulting Agreement for Interim CFO
Avanos Medical, Inc. has announced the end of the consulting agreement with Warren Machan, who has been serving as the company's Interim Chief Financial Officer. The agreement, which started on October 28, 2024, will terminate on May 31, 2025, or upon an earlier agreed date with 30 days' notice. Machan's compensation included a fixed monthly fee that increased from $45,000 to $60,000 starting March 1, 2025. He was also eligible for two $45,000 cash bonuses, contingent upon his satisfactory performance and that the agreement remains in effect through the respective end periods. The decision about his performance was at the discretion of the company's CEO. No further incentives were part of his contract. The conclusion of his tenure as interim CFO completes the arrangement stipulated in the consulting agreement with Avanos.
Operational EventEnd of Consulting Period for Amar Murugan
The consulting agreement between Amar Murugan and Atara Biotherapeutics, Inc. is set to end on July 11, 2025. Murugan, previously the Chief Legal Officer at Atara, transitioned to a consultancy role after his employment ended on November 8, 2024. Under the consulting agreement, Murugan is required to work up to 10 hours per month at an hourly rate of $250, relinquish all stock options, and maintain vesting of his restricted stock units during the term. He is entitled to bonuses contingent upon FDA approval and the transfer of tabelecleucel manufacturing to Pierre Fabre Medicament. This transition is significant for Atara, as tabelecleucel is a key asset and its successful commercialization will have financial implications for the company.
Consulting Period EndConsulting Agreement with Branden Neish Ends
Weave Communications, Inc. announced the end of the consulting agreement with Branden Neish on September 16, 2025. Neish, who served as Chief Product and Technology Officer, will transition out of the company following his retirement, effective May 16, 2025. A Transition Agreement allows him to act as a consultant until the end date while facilitating the handover of his responsibilities to his successors. During this period, his unvested restricted stock units will continue to vest under existing terms, reflecting the company's intent to support Neish in his transition.
Consulting Agreement End